About DURECT (NASDAQ:DRRX)
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
Industry, Sector and Symbol
Trailing P/E Ratio-48.5
Forward P/E Ratio-9.70
Sales & Book Value
Annual Sales$49.17 million
Price / Sales6.05
Price / CashN/A
Book Value$0.14 per share
Price / Book13.86
Return on Equity-44.90%
Return on Assets-7.62%
DURECT (NASDAQ:DRRX) Frequently Asked Questions
What is DURECT's stock symbol?
DURECT trades on the NASDAQ under the ticker symbol "DRRX."
How were DURECT's earnings last quarter?
DURECT Co. (NASDAQ:DRRX) released its quarterly earnings results on Thursday, March, 1st. The specialty pharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.11. The specialty pharmaceutical company earned $19.54 million during the quarter, compared to analysts' expectations of $4.60 million. DURECT had a negative return on equity of 44.90% and a negative net margin of 7.51%. View DURECT's Earnings History.
When will DURECT make its next earnings announcement?
Where is DURECT's stock going? Where will DURECT's stock price be in 2018?
3 brokerages have issued 12 month target prices for DURECT's stock. Their predictions range from $2.00 to $3.50. On average, they anticipate DURECT's share price to reach $2.83 in the next twelve months. View Analyst Ratings for DURECT.
Who are some of DURECT's key competitors?
Some companies that are related to DURECT include Akebia Therapeutics (AKBA), Clementia Pharmaceuticals (CMTA), Aclaris Therapeutics (ACRS), Heska (HSKA), Oxford Biomedica (OXBDF), Five Prime Therapeutics (FPRX), MediciNova (MNOV), TiGenix - American Depositary Shares (TIG), Geron (GERN), Achillion Pharmaceuticals (ACHN), Keryx Biopharmaceuticals (KERX), Concert Pharmaceuticals (CNCE), BioCryst Pharmaceuticals (BCRX), Edge Therapeutics (EDGE), Achaogen (AKAO), Obseva (OBSV), Sinovac Biotech (SVA) and Synergy Pharmaceuticals (SGYP).
Who are DURECT's key executives?
DURECT's management team includes the folowing people:
- Felix D Theeuwes, Chairman, Chief Scientific Officer (Age 78)
- James E. Brown DVM, President, Chief Executive Officer and Director (Age 58)
- Matthew J. Hogan, Chief Financial Officer (Age 55)
- Judy R. Joice, Senior Vice President - Operations and Corporate Quality Assurance (Age 58)
- Myriam Theeuwes, Senior Vice President - Clinical Development
- David R. Hoffmann, Lead Independent Director (Age 70)
- Simon X. Benito, Independent Director (Age 72)
- Terrence F. Blaschke M.D., Independent Director (Age 72)
- Armand P. Neukermans Ph.D., Independent Director (Age 74)
- Jon S. Saxe J.D., Independent Director (Age 80)
Has DURECT been receiving favorable news coverage?
Media stories about DRRX stock have been trending somewhat positive on Monday, Accern reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT earned a news impact score of 0.24 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 45.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are DURECT's major shareholders?
DURECT's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.56%), Ingalls & Snyder LLC (5.79%), Tocqueville Asset Management L.P. (0.82%), Gagnon Securities LLC (0.77%), Renaissance Technologies LLC (0.46%) and Wells Fargo & Company MN (0.32%). Company insiders that own DURECT stock include April Fund LP 21, Dave Hoffmann and Felix Theeuwes. View Institutional Ownership Trends for DURECT.
Which institutional investors are selling DURECT stock?
DRRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tocqueville Asset Management L.P., Deutsche Bank AG and Gagnon Securities LLC. View Insider Buying and Selling for DURECT.
Which institutional investors are buying DURECT stock?
DRRX stock was bought by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Renaissance Technologies LLC, BlackRock Inc., SG Americas Securities LLC, Algert Global LLC and Wells Fargo & Company MN. Company insiders that have bought DURECT stock in the last two years include April Fund LP 21, Dave Hoffmann and Felix Theeuwes. View Insider Buying and Selling for DURECT.
How do I buy shares of DURECT?
Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DURECT's stock price today?
One share of DRRX stock can currently be purchased for approximately $1.94.
How big of a company is DURECT?
DURECT has a market capitalization of $297.47 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. DURECT employs 93 workers across the globe.
How can I contact DURECT?
DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.
MarketBeat Community Rating for DURECT (DRRX)MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
DURECT (NASDAQ:DRRX) Earnings History and Estimates Chart
DURECT (NASDAQ DRRX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2018||Q4 2017||($0.06)||$0.05||$4.60 million||$19.54 million||View||Listen|
|11/1/2017||Q3 2017||($0.05)||$0.04||$5.09 million||$20.75 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.07)||$5.17 million||$4.32 million||View||Listen|
|5/10/2017||Q1 2017||($0.06)||($0.06)||$3.60 million||$4.57 million||View||N/A|
|3/14/2017||Q4 2016||($0.06)||($0.06)||$3.03 million||$3.52 million||View||N/A|
|10/31/2016||Q316||($0.07)||($0.06)||$3.72 million||$37.00 million||View||Listen|
|8/1/2016||Q216||($0.06)||($0.07)||$3.69 million||$3.20 million||View||Listen|
|5/5/2016||Q116||($0.06)||($0.06)||$4.09 million||$3.60 million||View||Listen|
|2/29/2016||Q415||($0.06)||($0.05)||$4.83 million||$5.20 million||View||Listen|
|11/2/2015||Q315||($0.05)||($0.05)||$5.08 million||$4.70 million||View||Listen|
|8/3/2015||Q215||($0.06)||($0.05)||$5.01 million||$4.40 million||View||Listen|
|4/30/2015||Q115||($0.06)||($0.04)||$4.82 million||$4.77 million||View||Listen|
|3/2/2015||Q414||($0.05)||($0.05)||$4.32 million||$4.30 million||View||Listen|
|11/3/2014||Q3||($0.05)||($0.06)||$4.10 million||$4.26 million||View||Listen|
|8/7/2014||Q2||($0.05)||($0.05)||$3.90 million||$4.58 million||View||Listen|
|5/1/2014||Q1||($0.05)||($0.03)||$4.12 million||$6.30 million||View||Listen|
|2/27/2014||Q4||($0.06)||($0.05)||$2.79 million||$4.30 million||View||Listen|
|11/4/2013||Q3 2013||($0.06)||($0.06)||$3.57 million||$2.97 million||View||N/A|
|8/5/2013||Q2 2013||($0.05)||($0.05)||$3.42 million||$3.92 million||View||Listen|
|5/2/2013||Q1 2013||($0.06)||($0.05)||$3.78 million||$4.15 million||View||N/A|
DURECT (NASDAQ:DRRX) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.2 EPS
Next Year EPS Consensus Estimate: $-0.22 EPS
Dividend History for DURECT (NASDAQ:DRRX)
No dividend announcements for this company have been tracked by MarketBeat.com
DURECT (NASDAQ DRRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.30%
Institutional Ownership Percentage: 42.86%
DURECT (NASDAQ DRRX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/3/2016||April Fund L.P. 21||Major Shareholder||Buy||95,000||$1.16||$110,200.00|| |
|9/26/2016||April Fund L.P. 21||Major Shareholder||Buy||2,500,000||$1.15||$2,875,000.00|| |
|4/26/2016||April Fund L.P. 21||Major Shareholder||Buy||5,500,000||$1.25||$6,875,000.00|| |
|4/26/2016||Dave Hoffmann||Director||Buy||200,000||$1.25||$250,000.00||25,000|| |
|4/26/2016||Felix Theeuwes||Chairman||Buy||160,000||$1.25||$200,000.00|| |
|3/14/2016||Armand Neukermans||Director||Buy||18,000||$1.39||$25,020.00||1,250|| |
|3/14/2016||Felix Theeuwes||Chairman||Buy||70,000||$1.41||$98,700.00|| |
|3/10/2016||James E Brown||CEO||Buy||20,000||$1.33||$26,600.00||1,764,530|| |
|1/11/2016||April Fund Lp 21||Major Shareholder||Buy||300,100||$1.37||$411,137.00|| |
|9/29/2015||April Fund Ltd 21||Major Shareholder||Buy||952,249||$1.79||$1,704,525.71|| |
|3/10/2015||Simon X Benito||Director||Buy||40,000||$1.81||$72,400.00|| |
|3/9/2015||Felix Theeuwes||Chairman||Buy||225,600||$1.65||$372,240.00|| |
|3/6/2015||Felix Theeuwes||Chairman||Buy||380,000||$1.57||$596,600.00|| |
|11/21/2014||Felix Theeuwes||Chairman||Buy||72,700||$1.00||$72,700.00|| |
|11/20/2014||Felix Theeuwes||Chairman||Buy||136,015||$0.92||$125,133.80|| |
|11/8/2013||Felix Theeuwes||Chairman||Buy||714,285||$1.40||$999,999.00|| |
|9/10/2013||Felix Theeuwes||Chairman||Buy||75,000||$1.20||$90,000.00|| |
|9/9/2013||Felix Theeuwes||Chairman||Buy||25,000||$1.15||$28,750.00|| |
|6/4/2013||James E Brown||CEO||Buy||30,000||$0.80||$24,000.00|| |
|12/12/2012||Jon S Saxe||Director||Buy||15,000||$0.91||$13,650.00|| |
|11/14/2012||Felix Theeuwes||Chairman||Buy||100,000||$1.01||$101,000.00|| |
|8/28/2012||Jon S Saxe||Director||Buy||7,810||$0.97||$7,575.70|| |
|8/23/2012||Jon S Saxe||Director||Buy||5,000||$1.00||$5,000.00|| |
DURECT (NASDAQ DRRX) News Headlines
DURECT (NASDAQ:DRRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
DURECT (NASDAQ:DRRX) Income Statement, Balance Sheet and Cash Flow Statement
DURECT (NASDAQ DRRX) Stock Chart for Monday, March, 19, 2018